obesity/edema

The present invention relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof. More particularly, it relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof, which are adenosine antagonists and possess various pharmaceutical actions

BACKGROUND The peroxisome proliferator active receptors (PPARs), members of the nuclear hormone receptor superfamily, comprise several subtypes, such as PPAR.alpha., PPAR.beta., and PPAR.gamma.. The PPAR.gamma. subtype, also referred to as PPARG, is the target of the glitazone pharmaceutical agents

BACKGROUND The peroxisome proliferator active receptors (PPARs), members of the nuclear hormone receptor superfamily, comprise several subtypes such as PPAR.alpha., PPAR.beta., and PPAR.gamma.. The PPAR.gamma. subtype, also referred to as PPARG, is the target of the glitazone pharmaceutical agents

The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them. More particularly the present invention provides a compound of formula I ##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b

The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them. More particularly the present invention provides a compound of formula I ##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b

The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them. More particularly the present invention provides a compound of formula I ##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the 35 U.S.C. .sctn.371 national stage of PCT application PCT/JP2005/007354, filed Apr. 11, 2005, which claims priority to Japanese patent application No. 116725/2004, filed Apr. 12, 2004. The contents of these applications are incorporated

FIELD OF THE INVENTION This invention relates to novel substituted benzimidazol-2-ones. More particularly, the compounds of the present invention modulate the binding of the peptide hormone vasopressin and neuropeptide Y to their respective receptors and are therefore useful for treating conditions

BACKGROUND Caffeine is a central nervous system (CNS) stimulant belonging to the methylxanthine chemical class. It is the world's most widely consumed psychoactive drug. Caffeine affects several biological processes. The most prominent is reversibly blocking the action of adenosine on the adenosine

The present invention relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof. More particularly, it relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof, which are adenosine antagonists and posses various pharmaceutical actions